Movement Alert|Summit Therapeutics PLC Falls 4.1% in Regular Trading, FDA Complete Response Letter Continues to Weigh on Lung Cancer Drug Outlook

Market Focus11-17 22:52

On November 17, Summit Therapeutics PLC fell 4.1% in Regular Trading, trading at $11.33 per share, with turnover of $8.07 million.

The move follows the company’s disclosure that the FDA issued a complete response letter for ivonescimab in previously treated advanced lung cancer, meaning the current application was not approved and pressuring sentiment for the company’s lead asset.

According to the company update, the FDA concluded that progression-free survival benefit alone was insufficient to support a favorable benefit-risk profile without evidence of overall survival improvement. Summit Therapeutics PLC also did not provide a timeline for resubmission or specify what additional evidence it may submit, leaving the regulatory path and commercialization timing less certain. Earlier reports indicated the news had already triggered sharp premarket and intraday selling, and the continued weakness suggests the market is still repricing regulatory and development risk around ivonescimab.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment